Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
Public ClinicalTrials.gov record NCT00657150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)
Study identification
- NCT ID
- NCT00657150
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 2,055 participants
Conditions and interventions
Conditions
Interventions
- Enoxaparin Drug
- Dabigatran etexilate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2008
- Primary completion
- Aug 31, 2009
- Completion
- Not listed
- Last update posted
- Jul 1, 2014
Started 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1160.64.01005 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 1160.64.01010 Boehringer Ingelheim Investigational Site | Aurora | Colorado | — | — |
| 1160.64.01009 Boehringer Ingelheim Investigational Site | Englewood | Colorado | — | — |
| 1160.64.01012 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1160.64.01006 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 1160.64.01003 Boehringer Ingelheim Investigational Site | Missoula | Montana | — | — |
| 1160.64.01007 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1160.64.01013 Boehringer Ingelheim Investigational Site | Conway | South Carolina | — | — |
| 1160.64.01002 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1160.64.01011 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00657150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2014 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00657150 live on ClinicalTrials.gov.